Target intelligence / Profile preview

Herpes simplex virus DNA polymerase UL42–UL30 protein-protein interface (UL42–UL30 interface)

Target
UL42–UL30 interface
Molecular classification
Enzyme (DNA polymerase catalytic subunit UL30), Accessory protein (Processivity factor UL42), Viral protein complex
01

Overview

The **UL42/UL30 protein-protein interface** refers to the molecular interaction between the **UL42 processivity factor** and the **UL30 DNA polymerase catalytic subunit** of herpes simplex virus type 1. UL30 provides DNA polymerase and exonuclease activities, while UL42 enhances processivity by binding both UL30 (primarily via its C-terminus) and DNA. The interaction occurs through a flexible contact region, mainly at UL30’s C-terminal segment and a connector loop within UL42, involving salt bridges and positively charged surfaces that tether DNA and promote long-chain synthesis. Disruption of this interface prevents the formation of a fully processive viral polymerase, critically impairing viral DNA replication and replication origin usage. Structural studies reveal that UL42 is a monomer with a classic family B polymerase fold and that it mediates nuclear import of the holoenzyme via a bipartite nuclear localization signal (NLS). Targeting the UL42–UL30 interface is considered a promising antiviral strategy to inhibit HSV infections, and its specificity for the viral complex presents a lower risk of host toxicity

Other names
HSV polymerase accessory-catalytic interfaceHSV-1 DNA polymerase–processivity factor interaction
02

Mechanism of action

Potential interface inhibitors would block the physical association between UL42 and UL30, preventing formation of a processive viral DNA polymerase holoenzyme and thereby inhibiting viral replication

03

Biological functions

DNA replicationViral genome synthesisNuclear import of viral polymerase complexRegulation of polymerase processivity
04

Disease associations

Infection (Herpes simplex virus, HSV)
05

Safety considerations

Targeting viral protein interfaces is less likely to cause host toxicity than human protein targets; however, specificity for the viral interface over host DNA polymerases must be ensuredResistance can arise if the virus mutates the interface
06

Interacting drugs

Direct protein-protein interface inhibitors are currently experimental and not clinically established; classical HSV polymerase inhibitors target the catalytic site rather than the interface

1 more in the full profile.

07

Biomarkers

Detection of UL42 and UL30 expression in infected cells can be used as markers for HSV replication

Beyond the preview

Go deeper on Herpes simplex virus DNA polymerase UL42–UL30 protein-protein interface (UL42–UL30 interface).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Herpes simplex virus DNA polymerase UL42–UL30 protein-protein interface (UL42–UL30 interface).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call